Aragen completes commercial-scale GMP manufacturing of Daretabart in 9 months
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Based in the global marketing function, he will be responsible for strengthening the company's visibility among sponsors, partners and industry stakeholders worldwide
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
The conference highlighted research suggesting that deuterium levels may influence key biological processes
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The filing is backed by results from the pivotal SERENA-6 Phase III trial
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
Subscribe To Our Newsletter & Stay Updated